Structure via PubChem · Public domain (PubChem)
tavaborole
Sign in to saveAlso known as 5-Fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole, 5-Fluoro-2,1-benzoxaborol-1(3H)-ol, AN2690, AN 2690, AN-2690
Tavaborole, sold under the brand name Kerydin, is a topical antifungal medication for the treatment of onychomycosis, a fungal infection of the nail and nail bed with a complete clearance rate of 6-7% and partial clearance rate of 23-24% in individuals whose “infection border does not reach the cuticle at the base of the large toenail.” Tavaborole was approved by the US FDA in July 2014. The medication inhibits an essential fungal enzyme, leucyl-tRNA synthetase, that is required for protein synthesis. The inhibition of protein synthesis leads to termination of cell growth and then cell death,
Key facts
- Drug.image
- Tavaborole.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 150px
- Drug.image2
- Tavaborole ball-and-stick model.png
- Drug.image_class2
- bg-transparent
- Drug.width2
- 150px
- Drug.tradename
- Kerydin
- Drug.MedlinePlus
- a614049
- Drug.pregnancy_US
- N
- Drug.routes_of_administration
- Topical
- Drug.ATC_prefix
- D01
- Drug.ATC_suffix
- AE24
- Drug.legal_US
- Rx-only
- Drug.legal_status
- Rx-only
- Drug.CAS_number
- 174671-46-6
- Drug.PubChem
- 11499245
- Drug.DrugBank
- DB09041
- Drug.ChemSpiderID
- 9674047
via Wikipedia infobox
Chemical data
- Formula
- C7H6BFO2
- Molecular weight
- 151.93 g/mol
- IUPAC name
- 5-fluoro-1-hydroxy-3H-2,1-benzoxaborole
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2014
- Admin. routes
- topical
- Indications
- tinea, tinea unguium
via ChEMBL · EBI
Research
176 papers- Tavaborole.2006
- Efinaconazole and Tavaborole.Journal of pharmacy practice · 2017
- Tavaborole topical solution, 5% for the treatment of toenail onychomycosis.Drugs of today (Barcelona, Spain : 1998) · 2015
- Tavaborole - a treatment for onychomycosis of the toenails.Expert review of clinical pharmacology · 2016
- Antifungal agent tavaborole as a potential broad-spectrum serine and metallo-β-lactamases inhibitor.EBioMedicine · 2025
via PubMed
~3 min read
Encyclopedic overview
9 sectionsContents
- Medical uses
- Side effects
- Pharmacology
- Pharmacokinetics
- Society and culture
- Economics
- See also
- References
- External links
Tavaborole, sold under the brand name Kerydin, is a topical antifungal medication for the treatment of onychomycosis, a fungal infection of the nail and nail bed with a complete clearance rate of 6-7% and partial clearance rate of 23-24% in individuals whose “infection border does not reach the cuticle at the base of the large toenail.” Tavaborole was approved by the US FDA in July 2014. The medication inhibits an essential fungal enzyme, leucyl-tRNA synthetase, that is required for protein synthesis. The inhibition of protein synthesis leads to termination of cell growth and then cell death, eliminating the fungal infection.
==Medical uses== Tavaborole is used in the treatment of onychomycosis. In clinical trials, tavaborole was more effective than the vehicle (ethyl acetate and propylene glycol) alone in curing onychomycosis. In two studies, fungal infection was eliminated using tavaborole in 6.5% of the cases vs. 0.5% using the vehicle alone, and 27.5% vs. 14.6% using the vehicle alone.
Excerpted from Wikipedia’s “tavaborole” article, available under the CC BY-SA 4.0 licence.